The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Reducing CRS following epcoritamab in R/R FL: insights from an optimization cohort of EPCORE NHL-1
Umberto Vitolo, MD, Candiolo Cancer Institute, Turin, Italy, discusses an optimization cohort from the EPCORE NHL-1 trial (NCT03625037), investigating epcoritamab in relapsed/refractory (R/R) follicular lymphoma (FL). Additional measures, including a second intermediate dose on day 15 and dexamethasone prophylaxis, reduced the incidence and severity of cytokine release syndrome (CRS) while maintaining high response rates. Notably, these improvements were achieved in an outpatient setting, enhancing accessibility and convenience for patients. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
